Clinical Research Directory
Browse clinical research sites, groups, and studies.
8 clinical studies listed.
Filters:
Tundra lists 8 Left Ventricular (LV) Systolic Dysfunction clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07950137
AI-ECG Screening for Early Heart Failure Diagnosis
The goal of this parallel-group cluster randomized clinical trial is to evaluate whether opportunistic screening for left ventricular systolic dysfunction (LVSD), using an artificial intelligence algorithm applied to electrocardiograms (AI-ECG), increases the detection of previously unrecognized LVSD among adults aged ≥40 years receiving routine care in primary healthcare centers within the Brazilian Public Health System. LVSD is a key finding in the diagnosis of heart failure with reduced ejection fraction (HFrEF), a condition for which effective guideline-directed medical therapies are available but which remains underdiagnosed and undertreated. The study will also evaluate the effects of AI-ECG screening on clinical management, healthcare utilization, implementation outcomes, and healthcare costs. The main questions this study aims to answer are: 1. Does adding AI-ECG screening to usual clinical assessment increase the proportion of patients with newly identified LVSD (left ventricular ejection fraction \<50%) within six months compared with clinical assessment alone? 2. Does AI-ECG screening improve the use of echocardiography, the recognition by primary care teams, and the initiation or optimization of guideline-directed medical therapy for HFrEF? 3. How do LVSD detection rates differ between patients identified through AI-ECG screening alone and those identified through clinical suspicion alone? 4. Is this screening strategy feasible, acceptable, and cost-effective when implemented in primary healthcare? Primary healthcare centers will be randomized to either an intervention group, in which AI-ECG screening results will be provided alongside the standard ECG report, or a control group receiving usual care without AI-ECG results. Participants will: 1. Undergo a routine 12-lead electrocardiogram (ECG), as clinically indicated by their primary care physician. 2. Be referred for echocardiography based on clinical suspicion of LVSD in both groups or, additionally, a positive AI-ECG screening result in the intervention group. 3. Receive educational materials about HFrEF if newly diagnosed, while participating healthcare professionals will receive educational interventions on heart failure diagnosis and management. 4. Complete questionnaires evaluating educational interventions, when applicable. 5. Be followed for six months to assess newly identified LVSD, treatment initiation and optimization, healthcare utilization (including emergency visits and hospitalizations), mortality, implementation outcomes, and healthcare costs.
Gender: All
Ages: 40 Years - Any
Updated: 2026-11-20
1 state
NCT07795359
A Study Evaluating an Implantable Cardiac Microcurrent Device in Patients With Chronic Heart Failure
This study evaluates the safety and performance/effectiveness of the C-MIC System, an active implantable medical device designed to treat patients with heart failure with reduced ejection fraction (HFrEF). The system delivers a non-excitatory, constant direct electrical microcurrent (DC) to the heart with the aim of improving cardiac function. The C-MIC System is intended for use in patients with ischemic or non-ischemic dilated cardiomyopathy who have symptomatic, ambulatory heart failure despite receiving guideline-directed medical therapy. Eligible patients must have a left ventricular ejection fraction (LVEF) between ≥20% and ≤40%. The device is implanted in the catheterization laboratory using a minimally invasive procedure that does not require open-heart surgery. Following implantation, patients receive C-MIC Therapy for a duration of six months. The therapy is designed to improve left ventricular performance, as well as functional capacity and patient well-being, including 6-minute walk distance, quality of life, and New York Heart Association (NYHA) functional class.
Gender: All
Ages: 18 Years - 80 Years
Updated: 2026-08-31
NCT06920030
Performance of the Cardiac Microcurrent (C-MIC) System With a Less Invasively Placed Left Ventricular Lead
Patients with idiopathic dilated cardiomyopathy in heart failure (NYHA class III - IV) with a baseline left ventricular ejection fraction between ≥25% and ≤35%, and patients with non-ischemic cardiomyopathy in heart failure (NYHA class III-IV) with a baseline left ventricular ejection fraction \>40% and \<50% despite guideline-directed medical therapy, will receive C-MIC treatment in addition to optimal medical management. The device can be implanted without the need for open-heart surgery. Patients are assigned to one of two groups according to the indications under investigation. At the end of the study after 6 months, the C-MIC System will be turned off. The primary endpoint of the study is the absolute change in left ventricular ejection fraction after 6 months of treatment.
Gender: All
Ages: 18 Years - 75 Years
Updated: 2026-08-11
1 state
NCT07248202
Ketamine-lidocaine Versus Ketamine-fentanyl for Induction of Anesthesia in Patients With Left Ventricular Systolic Dysfunction Undergoing Elective Coronary Artery Bypass
This study compares ketamine/fentanyl versus ketamine/lidocaine in term of their impact on cerebral perfusion during CABG. No prior data address these effects, and the goal is to identify the induction regimen that better preserves cerebral oxygenation.
Gender: All
Ages: 21 Years - Any
Updated: 2026-08-07
NCT07578129
PASCAL Precision-GDMT Registry
The goal of this observational study is to demonstrate that successful tricuspid valve repair with the PASCAL Precision System in participants with at least severe tricuspid insufficiency and left ventricular dysfunction will be associated with an improvement in up-titration of guideline-directed medical therapy (GDMT). The main question it aims to answer is: Does the tricuspid insufficiency repair with the Pascal Precision System increases the dose of the medications used for heart failure therapy in the study population 12 months after tricuspid repair, as compared to the dose taken at baseline. Participants undergoing tricuspid repair and fulfilling all inclusion/exclusion criteria will be asked to answer heart failure assessment as well as quality of life questionnaires at baseline and at 12 months post intervention. Medication monitoring will be performed throughout the study.
Gender: All
Ages: 18 Years - Any
Updated: 2026-05-13
NCT07355023
AI-Enabled Electrocardiogram-Guided Guideline-Directed Medical Therapy on Incident Left Ventricular Dysfunction: A Target Trial Emulation Study
This multicenter retrospective study evaluates whether artificial intelligence-enabled electrocardiography (AI-ECG) can identify individuals at high risk for left ventricular dysfunction and whether targeted guideline-directed medical therapy can mitigate subsequent risk. Using a large multicenter cohort of patients with preserved left ventricular systolic function, the investigators applied an AI-ECG-based risk stratification approach and emulated a target trial to examine the association between guideline-directed therapies and the risk of incident left ventricular functional decline.
Gender: All
Ages: 18 Years - Any
Updated: 2026-01-21
1 state
NCT05411614
Hybrid Ablation of Atrial Fibrillation in Heart Failure
A randomised controlled trial to assess the efficacy of staged hybrid ablation when compared with standard catheter ablation in patients with non-paroxysmal atrial fibrillation (AF) and Heart Failure
Gender: All
Ages: 18 Years - Any
Updated: 2025-11-28
NCT06811519
AI-based Prediction of Cardiac Function Using Echocardiography and Body Composition Data (ECHO-FIT Study)
This prospective observational study (ECHO-FIT Study) aims to develop and validate a predictive model for cardiac function, particularly left ventricular ejection fraction (LVEF), by integrating echocardiographic measurements with body composition data obtained from the QCCUNIQ BC 720 device. The study plans to enroll 2,000 adult participants, comprising 1,000 individuals with normal LVEF (≥50%) and 1,000 with heart failure (LVEF \<50%), all of whom will undergo standard-of-care echocardiography and body composition analysis. By analyzing the relationships between key echocardiographic parameters (such as LVEF and diastolic function) and body composition measures (including fat mass, skeletal muscle mass, and total body water), we will develop a non-invasive prediction model capable of identifying individuals at higher risk of cardiac dysfunction. This innovative approach has the potential to enhance early detection and personalized management of heart failure, reduce dependence on resource-intensive diagnostic procedures, and ultimately improve patient outcomes.
Gender: All
Ages: 20 Years - Any
Updated: 2025-03-04
1 state